Showing results (1651-1660 of 3,100) with videos related to
Sort By:
Pageof 310
Expert Review of Anticancer Therapy|April 4, 2025
The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysisQing-Bo Wang, Jin Li, Zi-Jun Zhang, et al.Expert Review of Anticancer Therapy|April 4, 2025
Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative reviewMuhammad Awais, Abdul Rehman, Syed Sarmad BukhariExpert Review of Anticancer Therapy|April 19, 2025
An evaluation of epcoritamab as a treatment for relapsed or refractory follicular lymphomaFrancesca Bonello, Pio Manlio Mirko Frascione, Danilo Faraci, et al.Expert Review of Anticancer Therapy|May 28, 2025
Risk-reducing mastectomy in healthy women with BRCA mutation: a narrative reviewCalogero Cipolla, Giuseppa Scandurra, Daniela Sambataro, et al.Expert Review of Anticancer Therapy|May 26, 2025
Accuracy of high b-value diffusion-weighted imaging in identifying benign and malignant breast lesions: a systematic review and meta-analysisJupeng Zhang, Qi Wu, Xiqi Zhu, et al.Expert Review of Anticancer Therapy|May 24, 2025
Prostate cancer prediction through a hybrid deep learning method applied to histopathological imageP Poonkuzhali, R Krishnamoorthy, Divya Nimma, et al.Expert Review of Anticancer Therapy|February 9, 2026
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencingAbdul Rahman Al Armashi, Jenny Gong, Pedro Barata, et al.Expert Review of Anticancer Therapy|January 25, 2026
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomasJohn RothmanExpert Review of Anticancer Therapy|February 5, 2026
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysisJianwei Ji, Taoying Li, Zhanwu Li, et al.Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.Pageof 310